AOD-9604 vs MOTS-c
GH-fragment lipolysis versus mitochondrial AMPK activation — two entirely different approaches to fat metabolism and body composition.
Comparison Overview
AOD-9604 and MOTS-c both target fat metabolism and body composition, but they approach the challenge from entirely different biological frameworks. AOD-9604 is a growth hormone fragment that isolates GH's lipolytic properties, directly stimulating fat breakdown through hormone-sensitive lipase activation while preventing new fat formation. MOTS-c is a mitochondrial-derived peptide that activates AMPK, the cellular energy sensor, producing exercise-mimetic metabolic effects including enhanced glucose uptake, fatty acid oxidation, and mitochondrial biogenesis.
This distinction matters because it determines which individuals benefit most from each compound. AOD-9604 is essentially targeted lipolysis, breaking down stored fat without affecting hormonal axes, IGF-1, or blood glucose. MOTS-c is metabolic reprogramming, fundamentally shifting how cells handle energy, with implications that extend beyond fat loss to insulin sensitivity, mitochondrial health, and metabolic aging.
The choice between these compounds depends on whether the individual needs targeted fat metabolism assistance (AOD-9604) or comprehensive metabolic restoration (MOTS-c), and whether their metabolic profile can accommodate each compound's specific interactions.
Side-by-Side Specifications
| Specification | AOD-9604 | MOTS-c |
|---|---|---|
| Format | Lyophilized Powder | Lyophilized Powder |
| Amount | 5mg per vial | 10mg per vial |
| Purity | >99.0% | >99.2% |
| Molecular Weight | 1815.08 g/mol | 2174.64 g/mol |
Head-to-Head Scorecard
Direct Fat-Burning Effect
AOD-9604 provides more direct and targeted fat breakdown through hormone-sensitive lipase activation, its mechanism is specifically designed to stimulate lipolysis. MOTS-c promotes fat oxidation as one of many metabolic effects of AMPK activation, making its fat-burning effect broader but less focused.
Metabolic Breadth
MOTS-c's AMPK activation produces comprehensive metabolic effects: enhanced glucose uptake, insulin sensitivity improvement, fatty acid oxidation, mitochondrial biogenesis, and nuclear gene regulation. AOD-9604 is intentionally narrow, isolated lipolysis without affecting glucose, IGF-1, or other metabolic systems.
Safety Simplicity
AOD-9604 has the simpler safety profile because it doesn't affect blood glucose, IGF-1, or hormonal axes, reducing monitoring requirements. MOTS-c directly affects glucose metabolism and insulin sensitivity, requiring more careful monitoring especially in diabetic or pre-diabetic patients.
Longevity Relevance
MOTS-c has direct longevity associations, its levels decline with age, and specific genetic variants are linked to notable longevity in centenarian populations. Its mitochondrial biogenesis and AMPK activation address fundamental aging mechanisms. AOD-9604 addresses body composition but does not directly target aging pathways.
Clinical Evidence
AOD-9604 has Phase IIb clinical trial data in 300 obese patients showing significant weight loss, plus FDA GRAS status. MOTS-c has a landmark Cell Metabolism publication and strong preclinical data but less clinical trial experience in humans. AOD-9604's clinical development is further advanced.
When to Choose Each
Simple fat loss without hormonal concerns
For individuals who want targeted fat reduction without affecting their hormonal profile, blood glucose, or IGF-1 levels, AOD-9604 provides isolated lipolysis with minimal systemic effects. Its intentionally narrow mechanism means fewer variables to monitor and lower interaction risk with other medications or conditions. This makes it particularly suitable for individuals who need metabolic simplicity. A specialist would monitor body composition progress through DEXA scanning.
Metabolic syndrome with insulin resistance
When fat accumulation is accompanied by insulin resistance, elevated fasting glucose, or other metabolic syndrome markers, MOTS-c's AMPK-mediated metabolic reprogramming addresses the underlying dysfunction rather than just the fat storage symptom. Its insulin-sensitizing effects, enhanced glucose uptake, and mitochondrial biogenesis target the root metabolic impairment. However, this must be carefully monitored if taking diabetes medications, as AMPK activation shares pathways with metformin. A specialist would closely monitor glucose and adjust any diabetes medications.
Age-related metabolic decline
MOTS-c is uniquely relevant for age-related metabolic decline because it's a mitochondrial-derived peptide whose levels naturally decrease with age, paralleling the metabolic slowdown of aging. Its ability to stimulate mitochondrial biogenesis (creating new mitochondria), restore AMPK signaling, and improve exercise capacity directly addresses the hallmarks of metabolic aging. Centenarian population studies showing longevity-associated MOTS-c variants provide epidemiological support. A specialist would design a protocol integrated with overall longevity strategy.
Post-exercise body composition optimization
For active individuals optimizing body composition alongside training, AOD-9604's fasted morning lipolysis enhancement complements MOTS-c's exercise-mimetic metabolic effects. This combination provides targeted fat breakdown plus enhanced metabolic adaptation from training. However, combination protocols require specialist design to ensure dosing, timing, and monitoring are appropriate for the individual training load and metabolic status.
Mechanism Breakdown
AOD-9604 and MOTS-c operate through entirely unrelated biological pathways. AOD-9604 replicates the C-terminal fragment (amino acids 176-191) of human growth hormone, the specific structural domain responsible for GH's fat-metabolizing activity. It activates hormone-sensitive lipase (HSL) in adipocytes, catalyzing the hydrolysis of stored triglycerides into free fatty acids and glycerol. Simultaneously, it inhibits lipogenesis, the synthesis of new fat from circulating substrates. Critically, AOD-9604 does not interact with the GH receptor's growth-promoting or IGF-1-stimulating domains, providing isolated lipolysis without hormonal axis effects. MOTS-c operates from the mitochondrial genome, acting through metabolic signaling rather than hormone mimicry. It inhibits the folate cycle enzyme MTHFD, reducing de novo purine biosynthesis and accumulating AICAR, an endogenous AMPK activator. AMPK activation triggers a metabolic cascade: GLUT4 translocation for enhanced glucose uptake, PGC-1α activation for mitochondrial biogenesis, increased fatty acid β-oxidation, and under stress conditions, nuclear translocation for antioxidant gene regulation via ARE elements. The practical distinction: AOD-9604 tells fat cells to release their stores. MOTS-c reprograms cellular energy metabolism to preferentially burn fat while building new mitochondria and improving insulin signaling. One is a targeted metabolic tool; the other is a comprehensive metabolic reset.
View Full Compound Details
AOD-9604
GH Fragment 176-191, Targeted Lipolysis Without Hormonal Side Effects
- Targeted Lipolysis
- No Hormonal Side Effects
- Lipogenesis Prevention
- FDA GRAS Safety Status
MOTS-c
Mitochondrial-Derived Peptide, AMPK Activation for Metabolic Optimization
- Metabolic Optimization
- Exercise Capacity Enhancement
- Longevity-Associated Signaling
- Mitochondrial Function Support
Frequently Asked Questions
Their distinct mechanisms make combination theoretically complementary, AOD-9604 enhancing fat release while MOTS-c improving fat utilization and metabolic function. However, combination metabolic protocols require specialist design and monitoring, particularly because MOTS-c's effects on glucose metabolism must be tracked alongside any body composition changes.
AOD-9604 provides more direct, measurable fat loss through targeted lipolysis with Phase IIb clinical trial data. MOTS-c provides broader metabolic optimization that includes fat reduction but extends to insulin sensitivity, mitochondrial function, and exercise capacity. The choice depends on whether you need simple fat metabolism support (AOD-9604) or comprehensive metabolic restoration (MOTS-c). A specialist would recommend based on metabolic profile.
Both AOD-9604 and MOTS-c are research-quality compounds requiring qualified medical supervision. While AOD-9604 has a simpler monitoring profile (no glucose or IGF-1 effects), MOTS-c requires careful metabolic monitoring. Both benefit from baseline and ongoing body composition analysis and metabolic blood work.
No. One of AOD-9604's key design advantages is that it does not affect blood glucose or insulin sensitivity, confirmed in published research. This distinguishes it from full growth hormone and from MOTS-c (which directly modulates glucose metabolism). This makes AOD-9604 simpler to manage from a monitoring perspective.
MOTS-c activates AMPK, the same metabolic sensor activated by exercise, producing similar downstream effects on glucose uptake, fat oxidation, and mitochondrial biogenesis. However, exercise provides additional benefits (cardiovascular conditioning, musculoskeletal strengthening, neurological effects) that MOTS-c does not replicate. MOTS-c complements but does not replace physical activity.
Need help deciding between AOD-9604 and MOTS-c?
A specialist can evaluate which compound is most appropriate for your individual situation.
Speak with a Specialist Free initial consultation. No obligation.Reviewed by the Peptide Science Thailand Editorial Team.
Last reviewed: March 1, 2026